Bayer stops sales of Trasylol

clipped from www.myfoxal.com , Germany --  Bayer AG said Monday it has halted worldwide sales of its antibleeding drug Trasylol after a Canadian clinical study last month found that it could be linked to a higher risk of death than other drugs. Bayer Stops Sales of Trasylol Globally The drug is designed to stem blood less and enable patients receiving heart bypass surgery to avoid the use of transfusions. Last week the FDA said that accumulating evidence suggests Trasylol increased the risk of death compared with other drugs. Trasylol, also known as aprotinin, works by blocking enzymes that dissolve blood clots. That announcement came a month after FDA advisers recommended Trasylol remain on the market despite its links to an increased risk of death and other serious side effects. The agency began re-evaluating the drug's safety after the January 2006 publication of two studies that linked the drug's use to serious side effects, including kidney problems, heart attacks and strokes.